Log inTry free

Janux Therapeutics (JANX) stock

Market cap $1.0B

$16.54
-2.30%

Market closed. Prices as of Monday's close.

Quality Score
0
Below Average
In its industry
#148of 300
Biotech

JANX's Quality Score fell 1 point on Mon, Oct 5, to 0. Its weekly trend stopped pointing up (2 chart checks stopped).

Next2H 2026“…data from the Phase 1 healthy volunteer study of JANX011 expected to be announced in the second half of 2026…”Trial data · 8-K, Aug 6
Cash$971M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30

Follow JANX's trial news. Pro members can get an alert when Janux Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when JANX files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Cash$971M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30

What's next for JANX, and how long its cash lasts

From Janux Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

2H 2026“Initial clinical data from the Phase 1 healthy volunteer study of JANX011 expected to be announced in the second half of 2026.”Trial data · 8-K, Aug 6

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
JANX011 · Autoimmune · Phase Early 1
Its trial
JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.Phase Early 1 · Recruiting · 60 people · main data estimated Oct 2026 · NCT07291323

4 more trials, 3 more milestones and 26 filings, for Pro members.

Cash runway Jun 30 balance sheet

$971M in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed May 8, 2024)
  • At-the-market share sales program (S-3ASR, filed May 8, 2024)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

An officer, Janeen Noel Doyle, sold 4,059 shares on Jun 2. 7 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when David Campbell buys or sells

For Pro members: every trade, and David Campbell’s 15 filings and quotes.

Get an optional alert when JANX files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 113 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why JANX lags the market

Janux Therapeutics returned -28% over five years to the S&P 500's +91%; free cash flow went from -$4.4M to -$83.3M.

Sources: Price history, Oct 5, 2026; Annual reports, Dec 31, 2025

2 drivers, the timeline, and the peer table, for Pro members

Why JANX scores 0

Below AverageChoppy, 2 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

  • −3Long-term trend below a falling 200-⁠day average, down over one year, down over two years
  • +3Growth sales up 5,367% on the year, operating margin up 32403.9 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Chart checks adds
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Dilution, Volatility, Persistence, and News.

What every line is worth, and the reason behind it, on JANX and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 2:09 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Thu Nov 5, after the close

After its last 4 reports it closed -3.3% on average, higher 0 of 4 times.

What would turn JANX's score around: 6 things, for Pro members

Alert me when JANX's Quality Score turns up

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on JANX and every other stock.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

JANX has 2 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on JANX, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

  • RSI 1444.3

    Above 30, below 50.

  • MACD (12, 26, 9)Below signal

    Crossed below its signal line 17 sessions ago.

  • 50-day average$17.11

    The price is 3.3% below it.

  • 200-day average$15.00

    The price is 10.3% above it. The 50-day is above the 200-day, since Aug 26.

  • ADX 1417.9

    Under 25, with +DI below -DI.

  • Support$16.04

    Swing low from Sep 16, 3.0% below the price.

  • Resistance$16.59

    Swing high from Apr 20, 0.3% above the price.

  • Bollinger Bands (20, 2)Inside

    The bands run from $15.27 to $19.01.

  • Volume0.6x

    Against its 20-day average, for the time of day.

How JANX ranks in Biotech

JANX is #148 of 300 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

When does JANX report earnings, and what happens after?

Expected to report Thu Nov 5, after the close (in 30 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Aug 6, 2026After close-2.3%-1.6%-0.6%
May 7, 2026After close-0.7%-2.5%-1.0%
Feb 26, 2026After close-1.6%-1.4%+1.2%
Nov 6, 2025After close+1.7%-7.6%-4.2%

The gap is the next open against the close before the report; the reaction is where that session closed. JANX closed higher after 0 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

Who is trading JANX

JANX insider trades

One insider sold $57K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellJaneen Noel Doyle$57KChief Corp. & Bus. Dev. Ofcrat $14.03 on Jun 2, filed Jun 4

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

About Janux Therapeutics

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

113 employeesSan Diego, CAjanuxrx.com

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of JANX's score, with the points and the reason
  • All 14 checks on JANX and on all 3,243 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on JANX
BreakawayJun 4Janeen Noel Doyle sold JANX$57K at $14.03, filed Jun 4

What a filing on JANX would have sent. Alerts are optional.

See all 14 checks on JANXSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.